Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
OrigAMI-3: Amivantamab + FOLFIRI vs Cetuximab/Bevacizumab + FOLFIRI in RAS/BRAF Wild-type Metastatic Colorectal Cancer
jRCT2051240239Phase 3Recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Jan 2025
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, open-label trial of amivantamab in colorectal cancer (CRC), colorectal adenocarcinoma and metastatic colorectal adenocarcinoma (mCRC) (2 arms), sponsored by Janssen Pharmaceutical. Primary endpoints: Progression-Free Survival (PFS) by BICR and Overall Survival (OS). Started Jan 2025; status: recruiting.
02
Drugs
amivantamab
03
Conditions
colorectal cancer (CRC)colorectal adenocarcinomametastatic colorectal adenocarcinoma (mCRC)
Beyond the preview
Go deeper on jRCT2051240239.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2051240239.